RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
Clinical trials for RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising CAR-T therapy trial for lymphoma pulled before it started
Disease control TerminatedThis study was designed to test a new cell therapy called Liso-cel against standard treatments for adults with follicular lymphoma that came back or didn't respond to prior therapy. The goal was to see if Liso-cel could better control the disease and improve survival. However, th…
Matched conditions: RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
Phase: PHASE3 • Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC
-
New hope for lymphoma patients: drug duo aims to control cancer longer
Disease control OngoingThis study tests whether a new drug combination (mosunetuzumab plus lenalidomide) works better than a standard combination (rituximab plus lenalidomide) for people with follicular lymphoma that has returned or not responded to at least one prior treatment. About 478 adults with t…
Matched conditions: RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 03, 2026 12:02 UTC